Brain Tumors represent only a small fraction of the overall cancer diagnoses in the U.S. with 1.4% of new cases classified as brain or other nervous system cancers. National Cancer Institute (NCI) estimates 23,800 people to be diagnosed with brain cancer in 2017 and 16,700 people are projected to die (https://seer.cancer.gov/statfacts/html/brain.html). Additionally, the 5-year survival for these patients is reported to be 33.6%. Glioblastoma (GBM) is the most common malignant brain tumor in adults and is characterized by aggressive phenotype and poor prognosis. For GBM, 5-year survival rates are only 3-5%. One of the difficulties in treating GBM, and gliomas in general, is the amount of inter- and intra-tumoral heterogeneity present in these malignancies. However, advancements in molecular and sequencing technology have resulted in the molecular characterization of many recurrent genetic abnormalities in gliomas and hence affecting therapeutic management.